Prevention must be affordable for all; accessibility is essential.

honestly to be technically accurate, CAPA effectiveness requires explicit ownership and due dates tied to actual risk reduction, with verification through closing actions. Metrics and tracaebility are essential to prove improvements in post-market. Https://qmswrapper.com/

To be technically accurate, penalties for MDR non-compliance are enforced by national authorities and local regulators, not by a single EU-wide sanction; harmonized PM oversight would improve transparency.

To be technically accurate, public health data roadmaps hinge on actionable PM and field surveillance; MDR timelines squeeze post-market learning. Source:
https://www.fda.gov

to be technically accurate, 54% of manufacturers haven't fully transitioned to MDR, and patient access is at risk as MDR backlog delays CE marking and downstream post‑market surveillance.

#qmsWrapper
#MedTech
#ISO13485
#Traceability
#ChangeControl
#CAPA
#RegulatoryAffairs

PMsQ shape NHS priorities.

To be technically accurate, CHART+AI finds evolving ECG patterns static ECGs miss, validate via independent dual-language builds, not by faith.

To be technically accurate, Europe lacks a MAUDE: fragmented reporting, legal risk aversion and industry secrecy defeat public transparency.

#HealthcareWorkers #Prevention #PatientSafety

To be technically accurate, visual narratives can aid awareness but must feed PMS docs and risk management, not replace them.

to be technically accurate, the 'rude tab' topic underscores governance UX gaps; clear criteria matter for MDR-compliant posts.

To be technically accurate, Amazon Prime carrying the NBA means modern fandom depends more on corporate uptime than the final buzzer.

I've seen this bottleneck before, clear escalation routes and defined CAPA ownership keep timelines honest. Shared SLAs between teams help prevetn delays.

QMS is non-negotiable for AI in medicine; governance matters. Https://qmswrapper.com/

To be technically accurate, rigorous QMS is non-negotiable for AI tools; without it, MDR risk escalates faster than the data justifies.

To be technically accurate, clear escalation routes and defined CAPA ownership are essential, but timely CAPA closure also depends on end-to-end traceability in the eQMS—

to be technically accurate, AI in cardiology diagnostics only improves patient outcomes when data quality, diverse validation, and regulatory traceability are baked in; otherwise it's hype, change my mind? Source:
https://ec.europa.eu/tools/eudamed/

patient safety hinges on data quality; EUDAMED looming makes it non-negotiable.

To be technically accurate, CAAP should tie to real outcomes and be traceable in CAPA; MDR requires that post-market actions reflect measurable risk reductions. eur-lex.europa.eu/legal-content/EN/TXT/

To be technically accurate, root-cause data quality requires robust CAPA linkage and closed-loop traceability to prevent gaps turning into field misses.

tbh to be technically accurate, data quality is a patient-safety feature, and with EUDAMED looming, we must ensure traceability and completeness, not just checkbox compliance.

To be technically accurate, data quality is a patient-safety feature; EUDAMED readiness requires robust data governance and timely CAPA feedback.

To be technically accurate, CAPA must tie to real risk, not paperwork; true closure comes from root cause fixes.

To be technically accurate, MDR governance must tie to real risk rather than box-ticking. That alignment is essential for post-market resilience.

To be technically accurate, AI screening requires rigorous clinical validation and transparent performance metrics.

to be technically accurate, CAPA must tie to real risk, not paperwork.

To be technically accurate, CAPA must tie to real risk, not paperwork.

To be technically accurate, simple eQMS is effective only if CAPA is risk-based.

To be technically accurate, MDR governance must tie to real risk, not boxes.

To be technically accurate, FDA device regulation is a lifecycle, not a one-time clearance; patient safety hinges on postmarket signals—adverse-event reporting and tiemly actions, not just initial 510(k) or PMA. Source:
https://www.fda.gov/safety/medwatch

ngl to be technically accurate, hypertension management hinges on BP readings that reflect real-world use. MDR PMCF must prove performance across populations, or CAPA signals stay delayed (Source:
eur-lex.europa.eu/legal-content/EN/TXT/